Patient-reported Outcomes Following Percutaneous Ablation of Desmoid Tumors

Status

Enrolling by invitation

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07755176

Enrollment

Registered

2026-08-10

Start date

2026-09-01

Completion date

2028-12-31

Last updated

2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aggressive Fibromatoses, Desmoid Tumor

Brief summary

This study will evaluate patient-reported outcomes before and after percutaneous ablation of desmoid tumors. Adult participants undergoing ablation for desmoid tumor will complete surveys pre and post procedure to assess symptom burden, impact on daily life, early post-procedural pain and recovery, concomitant treatments, and radiological response following ablation.

Interventions

PROCEDUREDesmoid tumor ablation

Percutaneous ablation of desmoid tumor

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patients undergoing ablation for desmoid tumor.

Exclusion criteria

* Declines to participate in research.

Design outcomes

Primary

Measure	Time frame	Description
Change in desmoid tumor symptom severity following ablation	Baseline; 7 days; 1, 3, 6, 12, and 24 months post-ablation	Desmoid tumor symptom severity following ablation will be measured using the GODDESS© Desmoid Tumor Symptom Scale, a disease-specific patient-reported outcome measure assessing desmoid tumor-related symptoms. Scores will be calculated according to the validated GODDESS© scoring algorithm. Higher scores indicate greater symptom burden.
Change in desmoid tumor impact following ablation	Baseline; 7 days; 1, 3, 6, 12, and 24 months post-ablation	Desmoid tumor impact following ablation will be measured using the GODDESS© Desmoid Impact Scale, a disease-specific patient-reported outcome measure assessing desmoid tumor-related symptoms on patients' daily lives and functioning. Scores will be calculated according to the validated GODDESS© scoring algorithm. Higher scores are expected to indicate greater disease-related impact.
Change in post-procedural pain score	Baseline; 7 days; 1 month and 3 months post-ablation	The pain score is calculated from a 2 question self-report survey asking recipients to rate pain on a scale of 1-10. Higher scores indicate worse pain.

Secondary

Measure	Time frame	Description
Radiological response following ablation	Through 24 months post-ablation	Radiologic assessment of desmoid tumor response on follow-up imaging, including tumor response characteristics as available in the medical record.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORRebecca Hibbert, M.D.

Mayo Clinic

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 11, 2026